News


Resident News

Pendulum launched new product, probiotic for those w/ T2 Diabetes

By JLABS

Read full story
Resident News

Nkarta files for IPO

By JLABS

Read full story
Resident News

Biotech GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya

By JLABS

Read full story
Resident News

Applied Molecular Transport Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

By JLABS

Read full story
Resident News

Mammoth Biosciences On the Fast Company's 2020 World Changing Ideas Honorable Mentions

By JLABS

Read full story
Resident News

Ellis Day Product Launch & Featured on Product List in Forbes

By JLABS

Read full story
Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story
Other news

IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.

By Ideaya Biosciences

Read full story
Other news

Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets

By JLABS

Read full story
Other news

Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

By JLABS

Read full story
Other news

Ensysce Biosciences has received Fast Track designation from the FDA for the development of abuse-resistant opioid drug PF614

By JLABS

Read full story
Other news

Distributed Bio announces a deal to identify pre-optimized antibodies using their SuperHuman antibody library platform

By JLABS

Read full story
Other news

Arcturus Therapeutics expands collaboration with Takeda Pharmaceuticals

By JLABS

Read full story
Other news

Kara Bortone, Ph.D., Head of Johnson & JohnsonInnovation, JLABS in San Diego shares why her role is the coolest job in San Diego in San Diego Magazine

By JLABS

Read full story
Other news

Alumni, Batu Biologics, has secured $1.3M in crowdfunding to develop its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax

By JLABS

Read full story